This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Aug 23;345(8):618-9.

doi: 10.1056/NEJM200108233450814.

Cutaneous reactions to STI571

M Brouard, J H Saurat

PMID: 11529225
DOI: 10.1056/NEJM200108233450814

Comment

Cutaneous reactions to STI571

M Brouard et al. N Engl J Med. 2001.

. 2001 Aug 23;345(8):618-9.

doi: 10.1056/NEJM200108233450814.

Authors

M Brouard, J H Saurat

PMID: 11529225
DOI: 10.1056/NEJM200108233450814

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Druker BJ, et al. N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401. N Engl J Med. 2001. PMID: 11287972 Clinical Trial.

Similar articles

Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
Vano-Galvan S, Fernandez-Guarino M, Henriquez-Santana A, De Las Heras E, Calbacho M, Jaen P. Vano-Galvan S, et al. Eur J Dermatol. 2007 Nov-Dec;17(6):538-9. doi: 10.1684/ejd.2007.0273. Epub 2007 Oct 19. Eur J Dermatol. 2007. PMID: 17951138 No abstract available.
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Brouard MC, et al. Dermatology. 2001;203(1):57-9. doi: 10.1159/000051705. Dermatology. 2001. PMID: 11549802
Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y, Asahina A, Watanabe R, Fujimoto M, Ihn H, Tamaki K. Kuwano Y, et al. Int J Dermatol. 2006 Oct;45(10):1249-51. doi: 10.1111/j.1365-4632.2006.02930.x. Int J Dermatol. 2006. PMID: 17040457 No abstract available.
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW, O'Brien SG, Ford JM, Druker BJ. Deininger MW, et al. J Clin Oncol. 2003 Apr 15;21(8):1637-47. doi: 10.1200/JCO.2003.11.143. Epub 2003 Mar 13. J Clin Oncol. 2003. PMID: 12668652 Review.
[STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
Hasselbalch HC. Hasselbalch HC. Ugeskr Laeger. 2002 May 27;164(22):2914-7. Ugeskr Laeger. 2002. PMID: 12082821 Review. Danish.

See all similar articles

Cited by

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Musolino C, Allegra A, Mannucci C, Russo S, Alonci A, Maisano V, Calapai G, Gangemi S. Musolino C, et al. Turk J Haematol. 2015 Jun;32(2):168-71. doi: 10.4274/tjh.2014.0021. Turk J Haematol. 2015. PMID: 26316486 Free PMC article.
Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.
Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RC, Chang YC, Lu CW. Ng CY, et al. J Immunol Res. 2018 Jan 17;2018:5376476. doi: 10.1155/2018/5376476. eCollection 2018. J Immunol Res. 2018. PMID: 29577050 Free PMC article. Review.
Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor.
Hwang JE, Yoon JY, Bae WK, Shim HJ, Cho SH, Chung IJ. Hwang JE, et al. BMC Cancer. 2010 Aug 18;10:438. doi: 10.1186/1471-2407-10-438. BMC Cancer. 2010. PMID: 20718969 Free PMC article.
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.
Mughal TI, Schrieber A. Mughal TI, et al. Biologics. 2010 Dec 2;4:315-23. doi: 10.2147/BTT.S5775. Biologics. 2010. PMID: 21209726 Free PMC article.
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T. Widmer N, et al. Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6. Br J Cancer. 2008. PMID: 18475296 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information